OICR funding boost aims to speed the development of new drugs for some of the most common cancers
Congratulations to Dr. Saman Maleki on receiving funding from the Ontario Institute for Cancer Research (OICR) for this project entitled “Identifying an MLH1 small molecule inhibitor for combination with immune checkpoint inhibitors”. In this project, Dr. Maleki and his collaborators (Dr. Masoud Vedadi and Dr. Rima Al-awar) will undertake the development of a new drug that could make most types of cancers responsive to immunotherapy, including neuroblastoma, the most common cancer in infants, and breast cancer, the most common cancer in women. This could open a new line of treatment for those cancers and others.
The Ontario Institute for Cancer Research (OICR) continues to support Ontario drug discovery research by funding high-quality investigations of new therapies for some of the most prevalent pediatric and adult cancers.
